share_log

Stifel Initiates Coverage On Soleno Therapeutics With Buy Rating, Announces Price Target of $63

Benzinga ·  Jan 23 17:39

Stifel analyst Dae Gon Ha initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with a Buy rating and announces Price Target of $63.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment